Barclays
AXSM icon

Barclays’s Axsome Therapeutics AXSM Stock Holding History

Barclays’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-27,500
Closed -$2.19M – 4868
2024
Q1 		$2.19M Sell
27,500
-24,500
-47% -$2.06M ﹤0.01% 2480
2023
Q4 		$4.14M Buy
+52,000
New +$3.48M ﹤0.01% 2274
2020
Q2 		– Sell
-201,500
Closed -$11.9M – 5564
2020
Q1 		$11.9M Buy
201,500
+136,600
+210% +$11.1M 0.01% 902
2019
Q4 		$6.71M Buy
64,900
+45,000
+226% +$1.82M ﹤0.01% 1733
2019
Q3 		$403K Sell
19,900
-39,400
-66% -$1.01M ﹤0.01% 4415
2019
Q2 		$1.53M Sell
59,300
-37,800
-39% -$758K ﹤0.01% 3220
2019
Q1 		$1.38M Buy
+97,100
New +$902K ﹤0.01% 3035

Other funds holding AXSM

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Alethea Capital Management
Alethea Capital Management Mercer Island, Washington $197M AUM 51.86% 1-Year Est. Return

Barclays's AXSM Position: Q3 2026 in Review

Barclays reduced its Axsome Therapeutics (AXSM) stake by 31% in Q3 2026, selling an estimated $3.5M and leaving 35,125 shares worth $6.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1902.

Barclays first reported a position in AXSM in Q3 2016 and has held it in 34 quarters since. The position peaked at $17.6M in Q1 2024. 348 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Barclays held 35,125 shares of Axsome Therapeutics worth $6.48M as of Q3 2026.
  • Barclays sold 16,078 Axsome Therapeutics shares in Q3 2026, an estimated $3.5M.
  • Axsome Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1902 holding.
  • Barclays first reported a position in Axsome Therapeutics in Q3 2016 and has held it in 34 quarters since.
  • Barclays's Axsome Therapeutics position peaked at $17.6M in Q1 2024.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.